000 a
999 _c20254
_d20254
003 OSt
005 20231207101535.0
008 231207b xxu||||| |||| 00| 0 eng d
040 _aAIKTC-KRRC
_cAIKTC-KRRC
100 _922313
_aUbale, Shweta
245 _aDevelopment and validation of RP HPLC method for estimation of deferiprone and its related impurityin pharmaceutical dosage form
250 _aVol.13(1), Jan-Mar
260 _aRaipur
_bAsian Pharma Press
_c2023
300 _a1-6p.
520 _aAim of this study is to develop a new, precise, sensitive, simple, efficient, selective, and accurate high-performance liquid chromatographic method for the separation and determination of Deferiprone and its impurity in the capsule dosage form. A wide-range of literature survey disclosed no method for estimation said as the above. The chromatographic separation was achieved on Agilent Zorbax Bonus-RP (250 x 4.6mm, 5µ) with a mobile phase of Methanol: 0.1% O-Phosphoric acid (10:90, % v/v) combination in 1000ml of Methanol: Water (50: 50, % v/v) using a diluent. The flow rate of 1mL/min and UV detection at 280nm use as wavelength. The developed method was validated as reported by ICH guidelines. The linearity of the calibration curve for deferiprone and its process-related impurity in the concentration range of 4.0-6.0µg/ml. There exists a good correlation between peak area and analyte concentration. The retention time for deferiprone was discovered to be 2.29 min and its impurity was 8.65min. Deferiprone's relative standard deviation value is 0.45 and its process-related impurity is 0.17. All the results tell that the proposed method was highly sensitive, simple, precise, accurate, and fast. A large number of samples can be analyzed in a shorter time due to shorter retention times, so it can be successfully applied for routine analysis of Deferiprone and related impurity (maltol) in pharmaceutical dosage forms.
650 0 _94639
_aPHARMACEUTICS
700 _919810
_aBhosale, Mayur
773 0 _tAsian journal of pharmaceutical analysis
_x2231-5667
_dRaipur A & V Publications
856 _uhttps://ajpaonline.com/AbstractView.aspx?PID=2023-13-1-1
_yClick here
942 _2ddc
_cAR